European Primary Care Cardiovascular Society

ACC.21

EPCCS reports news from the virtual American College of Cardiology (ACC) Scientific Sessions 2021.

Increased risk of MACE with higher DHA levels adjusted for EPA

News - June 1, 2021

ACC 2021 In patients undergoing coronary angiography in the INSPIRE registry, higher levels of EPA unadjusted and adjusted for DHA were associated with lower MACE and in contrast, higher DHA levels adjusted for EPA were associated with higher MACE.

New-onset AF reduced by nonsteroidal MRA in DKD patients

News - June 1, 2021

ACC 2021 Risk of new-onset AF was reduced by 29% in patients randomized to finerenone compared to placebo in a population of patients with T2DM and CKD.

P2Y12i monotherapy as maintenance therapy after PCI

News - June 1, 2021

ACC 2021 In patients who had used DAPT for 6-18 months after PCI with DES, clopidogrel monotherapy as chronic maintenance therapy for 2 years reduced ischemic and bleeding outcomes compared to aspirin monotherapy.

IL-6 inhibition in CKD for CV risk reduction

5' education - June 1, 2021 - Prof. Paul Ridker, MD
Prof. Ridker talks about anti-inflammatory therapies to prevent CVD: What is the right drug and what is the right target population?

ACC 2021 Prof. Ridker talks about anti-inflammatory therapies to prevent CVD: What is the right drug and what is the right target population?

Reduction of hsCRP with novel IL-6 inhibitor in CKD with elevated hsCRP

News - June 1, 2021

ACC 2021 The phase 2 RESCUE trial showed that the IL-6 inhibitor ziltivekimab largely reduced hsCRP and other biomarkers of inflammation and thrombosis in patients with CKD and ≥2 mg/L hsCRP.

Comparing outcomes of ablation-based rhythm control vs. rate control in AF with HF

News - May 27, 2021

ACC 2021 Ablation-based rhythm control and rate control showed no statistically significant differences in the RAFT-AF trial for the primary outcome of all-cause mortality and HF events in patients with HF and high burden AF.

Association between alcohol consumption and discrete AF episode in the next four hours

News - May 27, 2021

ACC 2021 Results from the HOLIDAY study suggest that just one alcoholic drink was associated with a 2-fold greater odds and two or more alcoholic drinks were associated with a 3.5-fold greater odds of a discrete AF episode occurring in the next four hours.

Improved physical function by physical rehabilitation intervention in older patients with ADHF

News - May 27, 2021

ACC 2021 REHAB-HF showed that individualized physical rehabilitation intervention, compared to usual care, resulted in significant improvements in physical function, frailty status, quality of life, and depression in older patients with ADHF.

Controversy on omega-3FAs trials

5' education - May 27, 2021 - Prof. Eileen Handberg, PhD
In response to a new subanalysis of the STRENGTH trial, prof. Handberg discusses possible studies that can provide more insights to solve the controversy on omega-3FAs trials.

ACC 2021 In response to a new subanalysis of the STRENGTH trial, prof. Handberg discusses possible studies that can provide more insights to solve the controversy on omega-3FAs trials.

Proven safety with ARNI in MI patients, but no definite difference for primary endpoint

5' education - May 27, 2021 - Prof. Marc Pfeffer, MD, PhD
A short summary of the PARADISE-MI trial with sacubitril/valsartan compared to ramipril in MI patients is provided by prof. Pfeffer.

ACC 2021 A short summary of the PARADISE-MI trial with sacubitril/valsartan compared to ramipril in MI patients is provided by prof. Pfeffer.

Clinical outcomes not different with 81 mg vs. 325 mg aspirin in established CVD

5' education - May 26, 2021 - William Schuyler Jones, MD
In the ADAPTABLE trial, the efficacy and safety of 81 mg aspirin was compared to 325 mg aspirin. William Schuyler Jones tells us what these results mean for contemporary patients using 81 mg or 325 mg aspirin.

ACC 2021 In the ADAPTABLE trial, the efficacy and safety of 81 mg aspirin was compared to 325 mg aspirin. William Schuyler Jones tells us what these results mean for contemporary patients using 81 mg or 325 mg aspirin.

Reduction of CV events by dual SGLT1/2i in HF across full range of ejection fractions

News - May 26, 2021

ACC 2021 A pooled patient-level analysis showed that sotagliflozin significantly reduced total CV deaths, HF hospitalizations, and urgent visits for HF across the full range of baseline EF, including in patients with HFpEF.

ACC.21